Source: FDA, National Drug Code (US) Revision Year: 2024
Denosumab-bbdz is a human IgG2 monoclonal antibody that binds to human RANKL. Denosumab-bbdz has an approximate molecular weight of 147 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells.
Wyost (denosumab-bbdz) injection is a sterile, preservative-free, clear to slightly opalescent and colorless to slightly yellowish to slightly brownish solution for subcutaneous use.
Each single-dose vial of Wyost contains 120 mg denosumab-bbdz, glacial acetic acid (1.85 mg), polysorbate 20 (0.17 mg), sodium hydroxide (0.91 mg), sorbitol (78.9 mg), and Water for Injection (USP) with a pH of 5.2.
Hydrochloric acid and sodium hydroxide may be added to adjust pH.
| Dosage Forms and Strengths |
|---|
|
Injection: 120 mg/1.7 mL (70 mg/mL) clear to slightly opalescent and colorless to slightly yellowish to slightly brownish solution in a single-dose vial. |
| How Supplied | |||
|---|---|---|---|
|
Wyost injection is a clear to slightly opalescent and colorless to slightly yellowish to slightly brownish solution supplied in a single-dose vial. The vial stopper is not made with natural rubber latex.
Manufactured by: Sandoz Inc., Princeton, NJ 08540, U.S. License No. 2003 |
| Drug | Countries | |
|---|---|---|
| WYOST | Canada, Lithuania, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
